Hosted on MSN8d
Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade
Enanta Pharmaceuticals (ENTA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
Enanta Pharmaceuticals (NASDAQ:ENTA) Cut to “Sell” at StockNews.com
StockNews.com lowered shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) from a hold rating to a sell rating in a ...
Enanta Pharmaceuticals (ENTA) Receives a Sell from J.P. Morgan
In a report released yesterday, Eric Joseph from J.P. Morgan maintained a Sell rating on Enanta Pharmaceuticals (ENTA – Research Report), with ...
Enanta Pharmaceuticals (ENTA) Receives a Buy from Evercore ISI
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report) yesterday and set a price target of ...
President of Enanta Pharmaceuticals Picks Up 5.9% More Stock
Investors who take an interest in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) should definitely note that the President, Jay Luly, recently paid US$5.69 per share to buy US$256k worth of the stock.